ACADIA Pharmaceuticals Inc.
ACAD
Kedudukan dalam Saham
#4507
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Harga Saham
$19.76
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$3.40B
Perubahan (1 hari)
3.32%
Perubahan (1 tahun)
-5.66%
Negara
US
Perdagangan ACADIA Pharmaceuticals Inc. (ACAD)
Kategori
Healthcare
Bilangan saham terbitan bagi ACADIA Pharmaceuticals Inc. (ACAD)
Bilangan saham terbitan setakat June 2026: 171.60M
Menurut laporan kewangan terkini dan harga saham ACADIA Pharmaceuticals Inc., bilangan saham terbitan semasa ialah 171.60M. Pada akhir December 2023, syarikat mempunyai 163.82M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk ACADIA Pharmaceuticals Inc. (ACAD) dari 2000 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 171.60M | 3.55% |
| 2024 | 165.72M | 1.16% |
| 2023 | 163.82M | 1.32% |
| 2022 | 161.68M | 0.74% |
| 2021 | 160.49M | 2.01% |
| 2020 | 157.33M | 6.88% |
| 2019 | 147.20M | 16.29% |
| 2018 | 126.58M | 3.25% |
| 2017 | 122.60M | 5.82% |
| 2016 | 115.86M | 15.13% |
| 2015 | 100.63M | 3.48% |
| 2014 | 97.25M | 13.46% |
| 2013 | 85.72M | 56.23% |
| 2012 | 54.87M | 5.14% |
| 2011 | 52.18M | 35.21% |
| 2010 | 38.59M | 2.98% |
| 2009 | 37.48M | 0.98% |
| 2008 | 37.11M | 5.40% |
| 2007 | 35.21M | 26.10% |
| 2006 | 27.92M | 26.84% |
| 2005 | 22.01M | 112.63% |
| 2004 | 10.35M | 609.62% |
| 2003 | 1.46M | 0.48% |
| 2002 | 1.45M | 20.20% |
| 2001 | 1.21M | 12.90% |
| 2000 | 1.07M | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | 47.96% |
US
|
|
| 396.00M | 130.77% |
US
|
|
| 478.91M | 179.08% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -63.76% |
NL
|
